<?xml version='1.0' encoding='utf-8'?>
<document id="24477376"><sentence text="Improved ticagrelor antiplatelet effect on discontinuation of phenytoin."><entity charOffset="62-71" id="DDI-PubMed.24477376.s1.e0" text="phenytoin" /></sentence><sentence text="To report the influence of phenytoin on the antiplatelet effects of ticagrelor using a validated platelet aggregation study"><entity charOffset="27-36" id="DDI-PubMed.24477376.s2.e0" text="phenytoin" /><entity charOffset="68-78" id="DDI-PubMed.24477376.s2.e1" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.24477376.s2.e0" e2="DDI-PubMed.24477376.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24477376.s2.e0" e2="DDI-PubMed.24477376.s2.e1" /></sentence><sentence text="" /><sentence text="A 71-year-old man with coronary artery disease underwent percutaneous coronary intervention to revascularize several major coronary arteries" /><sentence text=" The patient was previously on phenytoin and was initiated on ticagrelor for antiplatelet therapy following stent placement"><entity charOffset="31-40" id="DDI-PubMed.24477376.s5.e0" text="phenytoin" /><entity charOffset="62-72" id="DDI-PubMed.24477376.s5.e1" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.24477376.s5.e0" e2="DDI-PubMed.24477376.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24477376.s5.e0" e2="DDI-PubMed.24477376.s5.e1" /></sentence><sentence text=" While the patient was receiving both drugs, platelet aggregation studies revealed less platelet inhibition than would be expected in a patient not taking a concomitant inducer of ticagrelor metabolism" /><sentence text=" On discontinuation of phenytoin, platelet inhibition improved"><entity charOffset="23-32" id="DDI-PubMed.24477376.s7.e0" text="phenytoin" /></sentence><sentence text="" /><sentence text="Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist following placement of coronary stents is critical to prevent stent thrombosis and subsequent myocardial infarction"><entity charOffset="31-38" id="DDI-PubMed.24477376.s9.e0" text="aspirin" /></sentence><sentence text=" Ticagrelor is a recently approved P2Y12 receptor antagonist that is subject to drug-drug interactions involving the hepatic cytochrome P450-3A4 enzyme system because of its metabolic elimination pathway"><entity charOffset="1-11" id="DDI-PubMed.24477376.s10.e0" text="Ticagrelor" /></sentence><sentence text=" This case demonstrates ticagrelor's drug-drug interaction with phenytoin through a platelet aggregation study and supports the manufacturer recommendation to avoid the combination of ticagrelor with any known inducers of cytochrome P450-3A4 metabolism"><entity charOffset="64-73" id="DDI-PubMed.24477376.s11.e0" text="phenytoin" /><entity charOffset="184-194" id="DDI-PubMed.24477376.s11.e1" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.24477376.s11.e0" e2="DDI-PubMed.24477376.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24477376.s11.e0" e2="DDI-PubMed.24477376.s11.e1" /></sentence><sentence text="" /><sentence text="The combination of ticagrelor and phenytoin may represent a potentially clinically significant drug-drug interaction because of phenytoin induction of ticagrelor metabolism and reduced P2Y12 receptor inhibition in patients who have recently undergone percutaneous coronary intervention and cardiac stent placement"><entity charOffset="19-29" id="DDI-PubMed.24477376.s13.e0" text="ticagrelor" /><entity charOffset="34-43" id="DDI-PubMed.24477376.s13.e1" text="phenytoin" /><entity charOffset="128-137" id="DDI-PubMed.24477376.s13.e2" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.24477376.s13.e0" e2="DDI-PubMed.24477376.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24477376.s13.e0" e2="DDI-PubMed.24477376.s13.e1" /><pair ddi="false" e1="DDI-PubMed.24477376.s13.e0" e2="DDI-PubMed.24477376.s13.e2" /><pair ddi="false" e1="DDI-PubMed.24477376.s13.e1" e2="DDI-PubMed.24477376.s13.e1" /><pair ddi="false" e1="DDI-PubMed.24477376.s13.e1" e2="DDI-PubMed.24477376.s13.e2" /></sentence><sentence text="" /></document>